Bibliography for Copy of MD7512 Clinical Presentation & Management of Diabetes: Complications & Cardiovascular Disease BETA

Abdul-Ghani, M. et al. (2017) ‘Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?’, Diabetes Care, 40(7), pp. 813–820. Available at: https://doi.org/10.2337/dc16-2736.

Adamsson Eryd, S. et al. (2017) ‘Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up’, Diabetic Medicine, 34(3), pp. 411–418. Available at: https://doi.org/10.1111/dme.13266.

Andersson, D.P. et al. (2017) ‘Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction’, Heart [Preprint]. Available at: https://doi.org/10.1136/heartjnl-2016-310746.

‘Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality.’ (no date) Prime [Preprint]. Available at: https://wwww.unboundmedicine.com/medline/citation/22586788/Assessing_the_relationship_between_admission_glucose_levels_subsequent_length_of_hospital_stay_readmission_and_mortality_.

Atkinson, M.A., Eisenbarth, G.S. and Michels, A.W. (2014) ‘Type 1 diabetes’, The Lancet, 383(9911), pp. 69–82. Available at: https://doi.org/10.1016/S0140-6736(13)60591-7.

Azmi, S. et al. (2017) ‘Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study’, Diabetologia [Preprint]. Available at: https://doi.org/10.1007/s00125-017-4245-z.

Bangalore, S. et al. (2011) ‘Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials’, Circulation, 123(24), pp. 2799–2810. Available at: https://doi.org/10.1161/CIRCULATIONAHA.110.016337.

Barzilay, J.I. et al. (2012) ‘Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study’, Circulation: Cardiovascular Quality and Outcomes, 5(2), pp. 153–162. Available at: https://doi.org/10.1161/CIRCOUTCOMES.111.962522.

Bianchi, C., Miccoli, R. and Del Prato, S. (2013a) ‘Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?’, Current Diabetes Reports, 13(3), pp. 403–410. Available at: https://doi.org/10.1007/s11892-013-0371-2.

Bianchi, C., Miccoli, R. and Del Prato, S. (2013b) ‘Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?’, Current Diabetes Reports, 13(3), pp. 403–410. Available at: https://doi.org/10.1007/s11892-013-0371-2.

Black, J.A. et al. (2014) ‘Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial’, British Journal of General Practice, 64(621), pp. e208–e216. Available at: https://doi.org/10.3399/bjgp14X677833.

Boulton, A.J. et al. (2009) ‘International collaborative research on Charcot’s disease - 2009’, The Lancet, 373(9658), pp. 105–106. Available at: https://doi.org/10.1016/S0140-6736(09)60019-2.

Boussageon, R. et al. (2011) ‘Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials’, BMJ, 343(jul26 1), pp. d4169–d4169. Available at: https://doi.org/10.1136/bmj.d4169.

Braffett, B.H., Wessells, H. and Sarma, A.V. (2016) ‘Urogenital Autonomic Dysfunction in Diabetes’, Current Diabetes Reports, 16(12). Available at: https://doi.org/10.1007/s11892-016-0824-5.

Çakici, N. et al. (2016a) ‘Systematic review of treatments for diabetic peripheral neuropathy’, Diabetic Medicine, 33(11), pp. 1466–1476. Available at: https://doi.org/10.1111/dme.13083.

Çakici, N. et al. (2016b) ‘Systematic review of treatments for diabetic peripheral neuropathy’, Diabetic Medicine, 33(11), pp. 1466–1476. Available at: https://doi.org/10.1111/dme.13083.

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947.

Cefalu, W.T. et al. (2016) ‘Getting to the "Heart” of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory”’, Diabetes Care, 39(5), pp. 664–667. Available at: https://doi.org/10.2337/dc16-0405.

Chatterjee, S., Khunti, K. and Davies, M.J. (2017) ‘Type 2 diabetes’, The Lancet [Preprint]. Available at: https://doi.org/10.1016/S0140-6736(17)30058-2.

Cheung, N., Mitchell, P. and Wong, T.Y. (2010) ‘Diabetic retinopathy’, The Lancet, 376(9735), pp. 124–136. Available at: https://doi.org/10.1016/S0140-6736(09)62124-3.

Chloe L. Edridge (2015) ‘Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies’, PLoS ONE, 10(6). Available at: https://doi.org/doi:  10.1371/journal.pone.0126427.

Clokie, M. et al. (2017) ‘New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium’, Diabetic Medicine, 34(3), pp. 305–315. Available at: https://doi.org/10.1111/dme.13313.

Dahlöf, B. et al. (2005) ‘Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial’, The Lancet, 366(9489), pp. 895–906. Available at: https://doi.org/10.1016/S0140-6736(05)67185-1.

Dana Dabelea (no date) ‘Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood’, JAMA, 317(8), pp. 825–835. Available at: https://doi.org/10.1001/jama.2017.0686.

Denig, P. et al. (2014) ‘Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial’, BMJ, 349(sep25 6), pp. g5651–g5651. Available at: https://doi.org/10.1136/bmj.g5651.

Dhatariya, K. et al. (2012) ‘NHS Diabetes guideline for the perioperative management of the adult patient with diabetes’, Diabetic Medicine, 29(4), pp. 420–433. Available at: https://doi.org/10.1111/j.1464-5491.2012.03582.x.

Dhatariya, K.K. and Vellanki, P. (2017) ‘Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA)’, Current Diabetes Reports, 17(5). Available at: https://doi.org/10.1007/s11892-017-0857-4.

‘Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies’ (2010) The Lancet, 375(9733), pp. 2215–2222. Available at: https://doi.org/10.1016/S0140-6736(10)60484-9.

‘Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death’ (2011) New England Journal of Medicine, 364(9), pp. 829–841. Available at: https://doi.org/10.1056/NEJMoa1008862.

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey (no date a). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321.

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey (no date b). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321.

‘Diabetic foot problems: prevention and management  | Guidance and guidelines | NICE’ (no date). Available at: https://www.nice.org.uk/guidance/ng19.

Duckworth, W. et al. (2009) ‘Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes’, New England Journal of Medicine, 360(2), pp. 129–139. Available at: https://doi.org/10.1056/NEJMoa0808431.

Dwamena, F. et al. (1996) ‘Interventions for providers to promote a patient-centred approach in clinical consultations’, in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. Available at: https://doi.org/10.1002/14651858.CD003267.pub2.

‘Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)’ (1998) The Lancet, 352(9131), pp. 854–865. Available at: https://doi.org/10.1016/S0140-6736(98)07037-8.

‘Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus’ (2010) New England Journal of Medicine, 362(17), pp. 1563–1574. Available at: https://doi.org/10.1056/NEJMoa1001282.

‘Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus’ (2005) Archives of Internal Medicine, 165(12). Available at: https://doi.org/10.1001/archinte.165.12.1410.

‘Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus’ (2010a) New England Journal of Medicine, 362(17), pp. 1575–1585. Available at: https://doi.org/10.1056/NEJMoa1001286.

‘Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus’ (2010b) New England Journal of Medicine, 362(17), pp. 1575–1585. Available at: https://doi.org/10.1056/NEJMoa1001286.

‘Effects of Intensive Glucose Lowering in Type 2 Diabetes’ (2008) New England Journal of Medicine, 358(24), pp. 2545–2559. Available at: https://doi.org/10.1056/NEJMoa0802743.

‘Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey’ (no date). Available at: https://www.clinicalkey.com/#!/content/journal/1-s2.0-S1262363617300022.

Ele Ferrannini (2015) ‘Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes’, European Heart Journal, 36(34), pp. 2288–2296. Available at: http://eurheartj.oxfordjournals.org/content/36/34/2288.

Elliott, W.J. and Meyer, P.M. (2007) ‘Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis’, The Lancet, 369(9557), pp. 201–207. Available at: https://doi.org/10.1016/S0140-6736(07)60108-1.

Ferrannini, E. and Cushman, W.C. (2012) ‘Diabetes and hypertension: the bad companions’, The Lancet, 380(9841), pp. 601–610. Available at: https://doi.org/10.1016/S0140-6736(12)60987-8.

Filippatos, T. et al. (2017) ‘Pathophysiology of diabetic dyslipidaemia’, Current Vascular Pharmacology, 15(999), pp. 1–1.

Fisher, L., Gonzalez, J.S. and Polonsky, W.H. (2014) ‘The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision’, Diabetic Medicine, 31(7), pp. 764–772. Available at: https://doi.org/10.1111/dme.12428.

Foresta, C. et al. (2017) ‘The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention’, Andrology [Preprint]. Available at: https://doi.org/10.1111/andr.12342.

Fox, C.S. et al. (2015) ‘Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association’, Diabetes Care, 38(9), pp. 1777–1803. Available at: https://doi.org/10.2337/dci15-0012.

‘Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes’ (2017) New England Journal of Medicine, 376(16), pp. 1507–1516. Available at: https://doi.org/10.1056/NEJMoa1612836.

Gæde, P. et al. (2008) ‘Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes’, New England Journal of Medicine, 358(6), pp. 580–591. Available at: https://doi.org/10.1056/NEJMoa0706245.

Gæde, P. et al. (2016) ‘Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial’, Diabetologia, 59(11), pp. 2298–2307. Available at: https://doi.org/10.1007/s00125-016-4065-6.

Game, F. (2016) ‘Classification of diabetic foot ulcers’, Diabetes/Metabolism Research and Reviews, 32, pp. 186–194. Available at: https://doi.org/10.1002/dmrr.2746.

Giorgino, F., Home, P.D. and Tuomilehto, J. (2016) ‘Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?’, Diabetes Care, 39(Supplement 2), pp. S187–S195. Available at: https://doi.org/10.2337/dcS15-3023.

Giovanni Corona (2016) ‘Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors’, PLoS ONE, 11(10). Available at: https://doi.org/doi:  10.1371/journal.pone.0157915.

Hayward, R.A. et al. (2015a) ‘Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 372(23), pp. 2197–2206. Available at: https://doi.org/10.1056/NEJMoa1414266.

Hayward, R.A. et al. (2015b) ‘Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 372(23), pp. 2197–2206. Available at: https://doi.org/10.1056/NEJMoa1414266.

Holman, R.R. et al. (2008) ‘10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes’, New England Journal of Medicine, 359(15), pp. 1577–1589. Available at: https://doi.org/10.1056/NEJMoa0806470.

Holman, R.R. et al. (2017) ‘Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 377(13), pp. 1228–1239. Available at: https://doi.org/10.1056/NEJMoa1612917.

Holt, R.I.G. (2010) Textbook of diabetes. 4th ed. Chichester: Wiley-Blackwell. Available at: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077.

Holt, R.I.G. et al. (2016) Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated. Available at: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056.

Holt, R.I.G. et al. (eds) (2017) Textbook of diabetes. Fifth edition. Chichester, West Sussex, UK: Wiley Blackwell. Available at: http://ezproxy.lib.le.ac.uk/login?url=http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=4769056.

Holt, R.I.G. (2017) ‘Understanding of the causes and management of diabetic foot disease’, Diabetic Medicine, 34(3), pp. 303–304. Available at: https://doi.org/10.1111/dme.13319.

Hotaling, J.M. et al. (2016a) ‘Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes’, Diabetes Care, 39(9), pp. 1587–1593. Available at: https://doi.org/10.2337/dc16-0059.

Hotaling, J.M. et al. (2016b) ‘Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes’, Diabetes Care, 39(9), pp. 1587–1593. Available at: https://doi.org/10.2337/dc16-0059.

Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011 (no date). Available at: http://www.nice.org.uk/guidance/cg127.

Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, , (no date) ‘Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges’, Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges [Preprint]. Available at: http://www.sciencedirect.com.ezproxy4.lib.le.ac.uk/science/article/pii/S0149291816307792.

‘Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey’ (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858717300335.

‘Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes’ (2008) New England Journal of Medicine, 358(24), pp. 2560–2572. Available at: https://doi.org/10.1056/NEJMoa0802987.

‘Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes’ (2005) New England Journal of Medicine, 353(25), pp. 2643–2653. Available at: https://doi.org/10.1056/NEJMoa052187.

Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998.

International Textbook of Diabetes Mellitus. 4th edn (2015). John Wiley & Sons, Incorporated. Available at: http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=1895437.

Jhamb, S., Vangaveti, V.N. and Malabu, U.H. (2016) ‘Genetic and molecular basis of diabetic foot ulcers: Clinical review’, Journal of Tissue Viability, 25(4), pp. 229–236. Available at: https://doi.org/10.1016/j.jtv.2016.06.005.

Jin, D. et al. (2010) ‘Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials’, Diabetes Research and Clinical Practice, 89(1), pp. 10–15. Available at: https://doi.org/10.1016/j.diabres.2010.03.021.

Johal, S. et al. (2017) ‘Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13383.

Kaul, S. (2017) ‘Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials’, Diabetes Care, 40(7), pp. 821–831. Available at: https://doi.org/10.2337/dc17-0291.

Khunti, K. et al. (2013) ‘Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people’, Diabetes Care, 36(11), pp. 3411–3417. Available at: https://doi.org/10.2337/dc13-0331.

Khunti, K. et al. (2015a) ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’, Diabetes Care, 38(2), pp. 316–322. Available at: https://doi.org/10.2337/dc14-0920.

Khunti, K. et al. (2015b) ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’, Diabetes Care, 38(2), pp. 316–322. Available at: https://doi.org/10.2337/dc14-0920.

Koye, D.N. et al. (2017) ‘Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13324.

Kunutsor, S.K., Seidu, S. and Khunti, K. (2017) ‘Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials’, Diabetic Medicine, 34(3), pp. 316–327. Available at: https://doi.org/10.1111/dme.13133.

Liew, G., Mitchell, P. and Wong, T.Y. (2009) ‘Systemic management of diabetic retinopathy’, BMJ, 338(feb12 1), pp. b441–b441. Available at: https://doi.org/10.1136/bmj.b441.

Lindholm, L.H. et al. (2002) ‘Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol’, The Lancet, 359(9311), pp. 1004–1010. Available at: https://doi.org/10.1016/S0140-6736(02)08090-X.

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036.

‘Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes’ (2011) New England Journal of Medicine, 364(9), pp. 818–828. Available at: https://doi.org/10.1056/NEJMoa1006524.

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey (no date a). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354.

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey (no date b). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354.

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey (no date c). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354.

Malavige, L.S. et al. (2015) ‘The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study’, European Journal of Medical Research, 20(1). Available at: https://doi.org/10.1186/s40001-015-0186-5.

Marso, S.P. et al. (2016) ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, 375(4), pp. 311–322. Available at: https://doi.org/10.1056/NEJMoa1603827.

Matheus, A.S. de M. et al. (2013) ‘Impact of Diabetes on Cardiovascular Disease: An Update’, International Journal of Hypertension, 2013, pp. 1–15. Available at: https://doi.org/10.1155/2013/653789.

Mayer-Davis, E.J. et al. (2017) ‘Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012’, New England Journal of Medicine, 376(15), pp. 1419–1429. Available at: https://doi.org/10.1056/NEJMoa1610187.

Melanie Davies (2016) ‘The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies’, Clinical Pharmacology : Advances and Applications, 8. Available at: https://doi.org/doi:  10.2147/CPAA.S82008.

Micha, R. et al. (2017) ‘Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States’, JAMA, 317(9). Available at: https://doi.org/10.1001/jama.2017.0947.

‘Microvascular Complications and Foot Care’ (2017) Diabetes Care, 40(Supplement 1), pp. S88–S98. Available at: https://doi.org/10.2337/dc17-S013.

Miller, M.E. et al. (2010) ‘The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study’, BMJ, 340(jan08 1), pp. b5444–b5444. Available at: https://doi.org/10.1136/bmj.b5444.

‘Minimizing Hypoglycemia in Diabetes: Table 1’ (2015) Diabetes Care, 38(8), pp. 1583–1591. Available at: https://doi.org/10.2337/dc15-0279.

Moreton, R.B.R. et al. (2017) ‘Factors determining uptake of diabetic retinopathy screening in Oxfordshire’, Diabetic Medicine, 34(7), pp. 993–999. Available at: https://doi.org/10.1111/dme.13350.

‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’ (2017) New England Journal of Medicine, 377(3), pp. 300–301. Available at: https://doi.org/10.1056/NEJMc1706292.

Navaneethan, S.D. et al. (2017) ‘Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD’, American Journal of Kidney Diseases [Preprint]. Available at: https://doi.org/10.1053/j.ajkd.2016.11.018.

Nicolucci, A. and Standl, E. (2011) ‘Antiplatelet Therapy for Every Diabetic Person?’, Diabetes Care, 34(Supplement_2), pp. S150–S154. Available at: https://doi.org/10.2337/dc11-s210.

Older antidiabetic drugs | The British Journal of Cardiology (no date). Available at: https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/.

Omland, T. et al. (2016) ‘Relation of Erectile Dysfunction to Subclinical Myocardial Injury’, The American Journal of Cardiology, 118(12), pp. 1821–1825. Available at: https://doi.org/10.1016/j.amjcard.2016.08.070.

Orchard, T.J. et al. (2015) ‘Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality’, JAMA, 313(1). Available at: https://doi.org/10.1001/jama.2014.16107.

P Naidoo (2015) ‘Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team’, The British Journal of Radiology, 88(1053). Available at: https://doi.org/doi:  10.1259/bjr.20150135.

Paul, S.K. et al. (2015) ‘Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes’, Cardiovascular Diabetology, 14(1). Available at: https://doi.org/10.1186/s12933-015-0260-x.

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey (no date a). Available at: https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020.

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey (no date b). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020.

Personalised treatment targets in type 2 diabetes patients: The Dutch approach - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626.

Pickering, R.J. et al. (2018) ‘Recent novel approaches to limit oxidative stress and inflammation in diabetic complications’, Clinical & Translational Immunology, 7(4). Available at: https://doi.org/10.1002/cti2.1016.

Piepoli, M.F. et al. (2016) ‘2016 European Guidelines on cardiovascular disease prevention in clinical practice’, Atherosclerosis, 252, pp. 207–274. Available at: https://doi.org/10.1016/j.atherosclerosis.2016.05.037.

Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862.

Rawshani, Aidin et al. (2017a) ‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’, New England Journal of Medicine, 376(15), pp. 1407–1418. Available at: https://doi.org/10.1056/NEJMoa1608664.

Rawshani, Aidin et al. (2017b) ‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’, New England Journal of Medicine, 376(15), pp. 1407–1418. Available at: https://doi.org/10.1056/NEJMoa1608664.

Ray, K.K. et al. (2009) ‘Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials’, The Lancet, 373(9677), pp. 1765–1772. Available at: https://doi.org/10.1016/S0140-6736(09)60697-8.

Richard W. Nesto (2008) ‘LDL cholesterol lowering in type 2 diabetes: what is the optimum approach?’, Clinical Diabetes, 26(1). Available at: http://go.galegroup.com/ps/i.do?id=GALE|A174972167&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=07d8e79bb8f42665bb52cc5732948c88.

Ritholz, M.D., MacNeil, T. and Weinger, K. (2017a) ‘Difficult conversations: adults with diabetes and the discussion of microvascular complications’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13419.

Ritholz, M.D., MacNeil, T. and Weinger, K. (2017b) ‘Difficult conversations: adults with diabetes and the discussion of microvascular complications’, Diabetic Medicine, 34(10), pp. 1447–1455. Available at: https://doi.org/10.1111/dme.13419.

Romero-Aroca, P. et al. (2017a) ‘Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study’, British Journal of Ophthalmology [Preprint]. Available at: https://doi.org/10.1136/bjophthalmol-2016-310063.

Romero-Aroca, P. et al. (2017b) ‘Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study’, British Journal of Ophthalmology [Preprint]. Available at: https://doi.org/10.1136/bjophthalmol-2016-310063.

Romero-Aroca, P. et al. (2017c) ‘Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study’, British Journal of Ophthalmology [Preprint]. Available at: https://doi.org/10.1136/bjophthalmol-2016-310063.

Rosenberg, J.B. and Tsui, I. (2017) ‘Screening for Diabetic Retinopathy’, New England Journal of Medicine, 376(16), pp. 1587–1588. Available at: https://doi.org/10.1056/NEJMe1701820.

Saha, S.A. and Arora, R.R. (2010) ‘Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials’, International Journal of Cardiology, 141(2), pp. 157–166. Available at: https://doi.org/10.1016/j.ijcard.2008.11.211.

Santi, D. et al. (2016) ‘Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial’, European Journal of Endocrinology, 174(4), pp. 513–522. Available at: https://doi.org/10.1530/EJE-15-1100.

Schrier, R.W., Estacio, R.O. and Jeffers, B. (1996) ‘Appropriate Blood Pressure Control in NIDDM (ABCD) Trial’, Diabetologia, 39(12), pp. 1646–1654. Available at: https://doi.org/10.1007/s001250050629.

Scott, A.R. (2015) ‘Management of hyperosmolar hyperglycaemic state in adults with diabetes’, Diabetic Medicine, 32(6), pp. 714–724. Available at: https://doi.org/10.1111/dme.12757.

Seidu, S. et al. (2016) ‘Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials’, Diabetic Medicine, 33(3), pp. 280–289. Available at: https://doi.org/10.1111/dme.12885.

Soliman, E.Z. et al. (2017) ‘Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study’, Diabetes Care, 40(6), pp. 793–799. Available at: https://doi.org/10.2337/dc16-2050.

Solomon, S.D. et al. (2017a) ‘Diabetic Retinopathy: A Position Statement by the American Diabetes Association’, Diabetes Care, 40(3), pp. 412–418. Available at: https://doi.org/10.2337/dc16-2641.

Solomon, S.D. et al. (2017b) ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’, Diabetes Care, 40(6), p. 809.3-809. Available at: https://doi.org/10.2337/dc17-er06e.

Solomon, S.D. et al. (2017c) ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’, Diabetes Care [Preprint]. Available at: https://doi.org/10.2337/dc17-er06e.

Solomon, S.D. et al. (2017d) ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’, Diabetes Care [Preprint]. Available at: https://doi.org/10.2337/dc17-er06e.

Sultan, A. et al. (2017a) ‘Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13364.

Sultan, A. et al. (2017b) ‘Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study’, Diabetic Medicine [Preprint]. Available at: https://doi.org/10.1111/dme.13364.

The changing face of diabetes complications - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109.

‘The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus’ (1993) New England Journal of Medicine, 329(14), pp. 977–986. Available at: https://doi.org/10.1056/NEJM199309303291401.

The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey (no date). Available at: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728.

The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check (no date). Available at: http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/.

Turnbull, F.M. et al. (2009a) ‘Intensive glucose control and macrovascular outcomes in type 2 diabetes’, Diabetologia, 52(11), pp. 2288–2298. Available at: https://doi.org/10.1007/s00125-009-1470-0.

Turnbull, F.M. et al. (2009b) ‘Intensive glucose control and macrovascular outcomes in type 2 diabetes’, Diabetologia, 52(11), pp. 2288–2298. Available at: https://doi.org/10.1007/s00125-009-1470-0.

‘Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE’ (no date). Available at: https://www.nice.org.uk/guidance/ng17.

‘Type 2 diabetes in adults: management | Guidance and guidelines | NICE’ (no date). Available at: https://www.nice.org.uk/guidance/ng28.

UK Prospective Diabetes Study Group (1998) ‘Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38’, BMJ : British Medical Journal, 317(7160). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28659/.

Umpierrez, G. and Korytkowski, M. (2016a) ‘Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia’, Nature Reviews Endocrinology, 12(4), pp. 222–232. Available at: https://doi.org/10.1038/nrendo.2016.15.

Umpierrez, G. and Korytkowski, M. (2016b) ‘Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia’, Nature Reviews Endocrinology, 12(4), pp. 222–232. Available at: https://doi.org/10.1038/nrendo.2016.15.

Valencia, W.M. and Florez, H. (2017) ‘How to prevent the microvascular complications of type 2 diabetes beyond glucose control’, BMJ [Preprint]. Available at: https://doi.org/10.1136/bmj.i6505.

Wannamethee, S.G. et al. (2011) ‘Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel rosk factors’, Archives of Internal Medicine, 171(5). Available at: https://doi.org/10.1001/archinternmed.2011.2.

Webb, D.R. et al. (2016) ‘Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes’, Diabetes/Metabolism Research and Reviews [Preprint]. Available at: https://doi.org/10.1002/dmrr.2877.

Weber, M.A. et al. (2010) ‘Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes’, Journal of the American College of Cardiology, 56(1), pp. 77–85. Available at: https://doi.org/10.1016/j.jacc.2010.02.046.

Whelton, P.K. (2005) ‘Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia’, Archives of Internal Medicine, 165(12). Available at: https://doi.org/10.1001/archinte.165.12.1401.

White, J. et al. (2016) ‘Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes’, JAMA Cardiology, 1(6). Available at: https://doi.org/10.1001/jamacardio.2016.1884.

Wong, M.G. et al. (2016a) ‘Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON’, Diabetes Care, 39(5), pp. 694–700. Available at: https://doi.org/10.2337/dc15-2322.

Wong, M.G. et al. (2016b) ‘Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON’, Diabetes Care, 39(5), pp. 694–700. Available at: https://doi.org/10.2337/dc15-2322.

Yavuz, M. et al. (2017) ‘Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration’, Diabetes Care, 40(2), pp. e14–e15. Available at: https://doi.org/10.2337/dc16-2204.

Yudkin, J.S., Richter, B. and Gale, E.A. (2011) ‘Intensified glucose control in type 2 diabetes—whose agenda?’, The Lancet, 377(9773), pp. 1220–1222. Available at: https://doi.org/10.1016/S0140-6736(10)61112-9.

Zaccardi, F., Webb, D.R., Davies, M.J., Dhalwani, N.N., Gray, L.J., et al. (2017) ‘Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation’, Diabetologia [Preprint]. Available at: https://doi.org/10.1007/s00125-017-4235-1.

Zaccardi, F., Webb, D.R., Davies, M.J., Dhalwani, N.N., Housley, G., et al. (2017) ‘Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England’, Diabetes, Obesity and Metabolism [Preprint]. Available at: https://doi.org/10.1111/dom.12941.

Zhang, C.-Y. et al. (2010) ‘Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis’, Annals of Medicine, 42(4), pp. 305–315. Available at: https://doi.org/10.3109/07853891003796752.

Zinman, B. et al. (2015) ‘Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes’, New England Journal of Medicine, 373(22), pp. 2117–2128. Available at: https://doi.org/10.1056/NEJMoa1504720.

Zoungas, S. et al. (2017) ‘Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials’, The Lancet Diabetes & Endocrinology, 5(6), pp. 431–437. Available at: https://doi.org/10.1016/S2213-8587(17)30104-3.